Product Description
Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Group Livzon Pharmaceutical Factory
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20242697 | N/A |
Completed |
Schizophrenia |
2024-11-05 |
|
CTR20241052 | N/A |
Completed |
Schizophrenia |
2024-09-24 |
|
ChiCTR2200063354 | N/A |
Not yet recruiting |
Depressive Disorder, Major |
2023-12-31 |
|
ChiCTR2200063355 | N/A |
Recruiting |
Schizophrenia |
2023-12-31 |
|
CTR20222399 | N/A |
Completed |
Schizophrenia |
2023-03-03 |
|
CTR20221170 | N/A |
Completed |
Schizophrenia |
2022-09-06 |
|
CTR20220126 | N/A |
Completed |
Schizophrenia |
2022-03-02 |
|
CTR20212498 | N/A |
Completed |
Schizophrenia |
2021-11-24 |
|
NCT04826510 | P4 |
Unknown status |
Depressive Disorder |
2021-06-30 |
|
CTR20244956 | N/A |
Recruiting |
Schizophrenia |
None |